MedElevator
Войти в исследования Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026
Preliminary results of the STARLORD study: a mono-institutional prospective phase II experience of STereotActic Radiotherapy for LOcally advanced non small cell lung cancer ineligible for concurrent chemoRaDiation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cuccia F, Campione M, Mortellaro G, Figlia V, Spera A, Napoli C, D'Alessandro S, Blasi L, Verderame F, Azzarello F, Failla G, Carruba G, Ferrera G
Аннотация
AIMS: For patients with unresectable stage III non-small cell lung cancer (NSCLC) ineligible for concurrent chemo-radiation (cCRT), stereotactic body radiotherapy (SBRT) may provide a favorable efficacy-toxicity balance.
MATERIALS AND METHODS: STARLORD (STereotActic Radiotherapy for LOcally advanced non--small cell lung cancer ineligible for concurrent chemoRaDiation) is a prospective phase II study evaluating safety and early outcomes of SBRT after chemotherapy is delivered with Radixact system.
RESULTS: Twenty-six consecutive patients with stage IIIB-IIIC NSCLC were analyzed with median age 75.5 years (IQR, 72.2-79.8), with 84.6% of patients presenting stage IIIB disease and 15.4% stage IIIC. Following induction chemotherapy, SBRT was delivered to both the primary tumor and mediastinal disease in 5 fractions, for median total doses, respectively, of 40 Gy (IQR, 40-45 Gy) and 35 Gy (IQR, 35-40 Gy). Consolidation immunotherapy was administered in 76.9% of patients. After a median follow-up of 17.3 months, acute grade 3 (G3) dysphagia was observed in 7.7%, no late grade ≥3 toxicities were observed. The 1-year local control (LC) rate was 86.7%, with two mediastinal progressions occurring 11 and 12 months after SBRT. Median distant progression-free survival (mDPFS) was 15.6 months with a 1-year DPFS rate of 56.7%. Four deaths were recorded during follow-up, resulting in a 1-year overall survival (OS) rate of 90.9%, with worse outcomes for patients with stage IIIC disease (log-rank P = .00027) and aged ≥75 years (log-rank P = .032).
CONCLUSIONS: In our experience, for frailer patients with unresectable locally advanced NSCLC, SBRT is well tolerated and provides promising disease control outcomes.
MATERIALS AND METHODS: STARLORD (STereotActic Radiotherapy for LOcally advanced non--small cell lung cancer ineligible for concurrent chemoRaDiation) is a prospective phase II study evaluating safety and early outcomes of SBRT after chemotherapy is delivered with Radixact system.
RESULTS: Twenty-six consecutive patients with stage IIIB-IIIC NSCLC were analyzed with median age 75.5 years (IQR, 72.2-79.8), with 84.6% of patients presenting stage IIIB disease and 15.4% stage IIIC. Following induction chemotherapy, SBRT was delivered to both the primary tumor and mediastinal disease in 5 fractions, for median total doses, respectively, of 40 Gy (IQR, 40-45 Gy) and 35 Gy (IQR, 35-40 Gy). Consolidation immunotherapy was administered in 76.9% of patients. After a median follow-up of 17.3 months, acute grade 3 (G3) dysphagia was observed in 7.7%, no late grade ≥3 toxicities were observed. The 1-year local control (LC) rate was 86.7%, with two mediastinal progressions occurring 11 and 12 months after SBRT. Median distant progression-free survival (mDPFS) was 15.6 months with a 1-year DPFS rate of 56.7%. Four deaths were recorded during follow-up, resulting in a 1-year overall survival (OS) rate of 90.9%, with worse outcomes for patients with stage IIIC disease (log-rank P = .00027) and aged ≥75 years (log-rank P = .032).
CONCLUSIONS: In our experience, for frailer patients with unresectable locally advanced NSCLC, SBRT is well tolerated and provides promising disease control outcomes.